Semantic Variant Primary Progressive Aphasia clinical trials at UCSF
2 research studies open to eligible people
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
open to eligible people ages 18-85
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
San Francisco, California
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
San Francisco, California and other locations
Our lead scientists for Semantic Variant Primary Progressive Aphasia research studies include Peter Ljubenkov Howie Rosen, MD Adam Boxer, MD, PhD.